Cytognos is a company specialising in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for haematological diseases. Cytognos’ employees joining BD as a result of the acquisition will continue to support employment stability in the Salamanca area in Spain.
Vitro has been a long-term investor in Cytognos since 1996, taking a majority stake in the company in 2018 to create a full platform player that integrates and commercialises flow cytometry reagents, hardware, and software. This add-on investment was Vitro’s first since GED Capital’s majority investment in the company in June 2017. Cytognos has since evolved into a full platform player in the clinical flow cytometry market.
“This important transaction with a leading global IVD company positions Vitro as a major player in the high-tech hospital diagnostics sector, which will be followed by the communication of other key corporate and technological achievements related to our molecular biology and anatomical pathology platforms,” said Javier Fernandez, CEO of Vitro.
The terms of the deal have not been disclosed.
Garrigues’ team was led by partner Ildefonso Polo and senior associate Beatriz Gimeno.
